Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Northern Trust Maintains Quarterly Dividend, Plans New Share Repurchase Authorization

Northern Trust Maintains Quarterly Dividend, Plans New Share Repurchase Authorization

MT newswireMT newswire2026/10/20 21:21
05:21 PM EDT, 10/20/2026 (MT Newswires) -- Northern Trust (NTRS) maintained its quarterly dividend at $0.88 per share, which is payable on Jan. 1 to shareholders on record as of Dec. 4, the company said late Tuesday. The company said its board also approved a new share repurchase program of up to $3.5 billion of its outstanding common stock. The new authorization will take effect upon completion of the current $2.5 billion share repurchase plan approved in July 2025, the company added.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver

Driven by booming semiconductor exports, South Korea's current account surplus in September surged to a record high.

智通财经•2026/11/05 02:41
South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver

CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

智通财经•2026/11/05 01:51
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response

According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.

智通财经•2026/11/05 01:36